- Home
- VNOM vs CDTX Comparison
VNOM vs CDTX Comparison
Compare VNOM & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VNOM | CDTX |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 6.9B |
| IPO Year | 2014 | 2015 |
Fundamental Metrics
Financial Performance| Metric | VNOM | CDTX |
|---|---|---|
| Price | $38.36 | $220.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 12 |
| Target Price | $53.36 | ★ $128.75 |
| AVG Volume (30 Days) | ★ 1.8M | 1.1M |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | ★ 6.30% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.93 | N/A |
| Revenue | ★ $1,131,200,000.00 | N/A |
| Revenue This Year | $56.75 | N/A |
| Revenue Next Year | $27.17 | N/A |
| P/E Ratio | $19.67 | ★ N/A |
| Revenue Growth | ★ 42.38 | N/A |
| 52 Week Low | $34.71 | $15.22 |
| 52 Week High | $52.10 | $221.20 |
Technical Indicators
Market Signals| Indicator | VNOM | CDTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.88 | 85.88 |
| Support Level | $37.70 | $219.91 |
| Resistance Level | $39.49 | $220.78 |
| Average True Range (ATR) | 1.17 | 0.71 |
| MACD | -0.22 | -4.25 |
| Stochastic Oscillator | 18.11 | 76.25 |
Price Performance
Historical ComparisonAbout VNOM Viper Energy Inc.
Viper Energy Inc is focused on owning and acquiring mineral and royalty interests in oil and natural gas properties in the Permian Basin. The Permian Basin is known to have a number of zones of oil and natural gas-bearing rock throughout.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.